|1.||Borghi, Claudio: 17 articles (01/2015 - 01/2003)|
|2.||Ambrosioni, Ettore: 13 articles (01/2015 - 01/2003)|
|3.||Omboni, Stefano: 12 articles (01/2015 - 01/2005)|
|4.||Bacchelli, Stefano: 8 articles (01/2015 - 06/2003)|
|5.||Malacco, Ettore: 5 articles (01/2009 - 01/2005)|
|6.||Vinereanu, Dragos: 4 articles (01/2015 - 01/2012)|
|7.||Degli Esposti, Daniela: 4 articles (01/2015 - 09/2004)|
|8.||Ambrosio, Giuseppe: 4 articles (01/2015 - 01/2012)|
|9.||Evangelista, Stefano: 4 articles (04/2014 - 02/2006)|
|10.||Cicero, Arrigo F G: 4 articles (06/2013 - 01/2006)|
01/01/2006 - "The Survival of Myocardial Infarction Long term Evaluation trials have demonstrated that the early administration of zofenopril to patients with acute myocardial infarction is associated with a significant reduction in the 6-week occurrence of major CV events in high-risk patients with anterior non-thrombolyzed myocardial infarction. "
01/01/2015 - "Early administration of zofenopril following acute myocardial infarction (AMI) proved to be prognostically beneficial in the four individual randomised, double-blind, parallel-group, prospective SMILE (Survival of Myocardial Infarction Long-term Evaluation) studies. "
06/01/2003 - "The present data suggest that the clinical outcome of patients with diabetes and myocardial infarction can be significantly improved by early treatment with zofenopril. "
06/01/2011 - "The SMILE studies have indicated positive results of the early administration (<24 hours) of zofenopril in patients with acute myocardial infarction (AMI). "
01/01/2008 - "To evaluate the clinical efficacy of the early administration of zofenopril in a group of patients with and without metabolic syndrome (MS+ and MS-) and anterior myocardial infarction enrolled in the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study. "
|2.||Hypertension (High Blood Pressure)
06/01/2013 - "This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril and ASA in the prevention of long-term cardiovascular outcomes also in the subgroup of patients with hypertension."
01/01/2011 - "The change in the dose-response curve, the increased proportion of controlled patients, and improved efficacy on nighttime BP values by bedtime administration of zofenopril should be taken into account when prescribing this ACEI for treatment of essential hypertension."
04/01/2014 - "Our findings establish that S-zofenopril improves vascular function by potentiating the H2S pathway in a model of spontaneous hypertension. "
01/01/2011 - "We studied 33 consecutive untreated hypertensive patients (19 men, 14 women), 56 +/- 12.7 years old, with grade 1 or 2 uncomplicated essential hypertension (according to the European Society of Hypertension-European Society of Cardiology guidelines) (diagnostic formulated by casual determination and confirmed by an ABPM session at baseline), using zofenopril as monotherapy. "
01/01/2007 - "There is a robust body of comparative data supporting zofenopril as an effective and well tolerated ACE inhibitor for treating hypertension. "
01/01/2009 - "Zofenopril is an antioxidant agent which has been shown to have beneficial effects in hypertension and heart failure. "
08/01/1996 - "Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. "
01/01/2012 - "In patients with LVD following AMI, the efficacy of zofenopril associated with ASA was superior to that of ramipril plus ASA, indicating some important clinical implications for the future use of ACEIs in patients with LVD or overt heart failure."
03/01/1993 - "In the current investigation, changes in autonomic tone associated with long-term administration of an angiotensin-converting enzyme inhibitor were measured using spectral analysis of heart rate variability in 13 patients with congestive heart failure who were enrolled in a double-blind randomized placebo-controlled trial of the angiotensin-converting enzyme inhibitor zofenopril. "
07/01/2013 - "A head-to-head evaluation of the effect of ramipril and zofenopril on the cardiovascular mortality rate of patients with chronic heart failure (HF) in the setting of clinical practice is not yet available. "
01/01/2011 - "Zofenopril-induced cough was generally of a mild to moderate intensity, occurred significantly (P < 0.001) more frequently in the first 3-6 months of treatment (3.0% vs 0.2% 9-12 months), and always resolved or improved upon therapy discontinuation. "
01/01/2011 - "Evidence from a limited number of studies indicates a relatively low incidence of zofenopril-induced cough. "
01/01/2011 - "Zofenopril doses of 30 mg and 60 mg resulted in significantly (P = 0.042) greater rate of cough (2.1% and 2.6%, respectively) than doses of 7.5 mg and 15 mg (0.4% and 0.7%, respectively). "
01/01/2011 - "The purpose of this paper is to give an overview on the epidemiology, pathophysiology, and treatment of ACE inhibitor-induced cough and to assess the incidence of cough induced by zofenopril treatment. "
01/01/2011 - "Data on the incidence of cough with the lipophilic third-generation ACE inhibitor zofenopril are scanty and never systematically analyzed. "
|5.||Left Ventricular Dysfunction
01/01/2013 - "Zofenopril is a viable and cost-effective treatment for managing patients with left ventricular dysfunction after acute myocardial infarction."
01/01/2013 - "In total, 771 patients with left ventricular dysfunction and acute myocardial infarction were randomized in a double-blind manner to receive zofenopril 60 mg/day (n = 389) or ramipril 10 mg/day (n = 382) + ASA 100 mg/day and were followed up for one year. "
06/01/2013 - "In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension. "
01/01/2013 - "In SMILE-4 (the Survival of Myocardial Infarction Long-term Evaluation 4 study), zofenopril + acetylsalicylic acid (ASA) was superior to ramipril + ASA in reducing the occurrence of major cardiovascular events in patients with left ventricular dysfunction following acute myocardial infarction. "
|3.||Aspirin (Acetylsalicylic Acid)
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|10.||Antihypertensive Agents (Antihypertensives)